Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 19,872 shares of the biopharmaceutical company’s stock after buying an additional 652 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Regeneron Pharmaceuticals were worth $14,155,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. UMB Bank n.a. lifted its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the last quarter. Trust Co. of Vermont raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 12 shares in the last quarter. Nvwm LLC lifted its position in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 14 shares during the last quarter. Moss Adams Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.6% during the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares in the last quarter. Finally, Westhampton Capital LLC increased its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $939,000 after buying an additional 15 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:REGN opened at $710.00 on Friday. The company has a market cap of $78.02 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The firm’s 50-day simple moving average is $716.62 and its 200-day simple moving average is $913.59. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $11.86 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Thursday, February 20th.

Wall Street Analyst Weigh In

A number of analysts have issued reports on REGN shares. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.